Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
08 Jul 2026 - 10 Jul 2026

Rapid Test Developed for Sickle Cell Anemia

By LabMedica International staff writers
Posted on 20 Sep 2011
A new blood test is being developed, which, for the first time, could help identify babies at risk of a severe form of sickle cell disease. More...


Babies with sickle cell disease have abnormal red blood cells and the test works by detecting these cells, which burst under certain conditions allowing an immediate diagnosis and more intensive treatment to be given.

Scientists from British Universities are collaborating to replace the diagnostic tests for sickle cell disease, which are complicated, requiring skilled technicians, and sophisticated and expensive equipment. Those tests are time consuming and are often not useful in an emergency situation. The newer test involves mixing a blood sample with a special sugar solution in low oxygen. Red blood cells from a baby who has sickle cell disease burst in the liquid, which becomes pink. Cells from a healthy baby do not burst, and the liquid stays clear.

None of the existing tests can predict how severe a baby's illness is likely to be. Babies who are at risk of the most severe symptoms, who might benefit greatly from early and intensive treatment, cannot be easily identified before they become poorly. Children with sickle cell disease face a lifetime of ill health. They have attacks of intense pain called crises, which can last several days. They are prone to infections and anemia, which can be life threatening. They are at risk of a variety of complications, including organ failure, strokes, and leg ulcers, and they have a shortened life expectancy.

An estimated 20 million people are affected worldwide and over 12,000 people in the UK have sickle cell disease, the country's most common severe genetic disorder. Symptoms usually start early in babies who are just six to nine months old. John Gibson, PhD, from the University of Cambridge (UK) is the project leader and working with colleagues at King's College Hospital, (London, UK) have enrolled 120 children and adults with sickle cell disease who will donate blood samples for testing. He said, "The aim of this project is to perfect the diagnostic test, so it can be used routinely at the bedside".

Related Links:
University of Cambridge
King's College Hospital


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.